

## Effect of Folate Targeted Immunotherapy on the Survival of Mice with Lung Tumor Implants




Fig. 1

# 24JK-FBP Tumor Imaging

FITC  
Fluorescence




FIG. 2

[illegible]

Э. Г. Я

U. t. e. a. t. d.

F-14 - F1TC  
-e-ated

Con-pe-t-lif

Filc-pe-t.tif

Transmitted

Can-per.tif

Filt-paper.tif

PF images

**Con-pe-g.tif**

Filc-pe-g.tif

FLTC: images

## Tumor Growth Curve\*




FIG. 4

# Effect of Cytokine Combinations on Folate-Targeted Immunotherapy\*




Fig. 5

# Immunotherapy Update\*




FIG. 6

## Synergistic Effect of FEFITC and IL-2 in Folate-Targeted Immunotherapy




Fig. 7

# The Effect of Mouse NK Cell Depletion on Folate Targeted Immunotherapy\*




Fig. 8



# Development of Cellular Immunity against the Parental M109 Tumor Cells





Fig. 9

-o- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/day), and IFN- $\alpha$  (25,000 U/day)

-▲-▼-◆- PBS control groups at respective tumor implantation time points



# IFN- $\alpha$ Further Enhances IL-2-augmented Immunotherapeutic Effect of FEFITC in Mice with Pre-existing Anti-FITC Antibody




Fig. 11

# Effect of Depletion of CD8<sup>+</sup> T cells on Folate-Targeted Immunotherapy




Fig. 12

# The Effect of a Third Cytokine, GM-CSF on Folate-Targeted Immunotherapy

## M109 Lung Carcinoma




Fig. 13

# **FEFITC-Targeted Immunotherapy: the IFN- $\alpha$ dosing effect on i.p. M109 Tumor**




Fig. 14

$\frac{1}{\sqrt{\pi}} \left( \frac{1}{\sqrt{\pi}} \right)^{-1} = \frac{1}{\sqrt{\pi}}$




Fig. 15

# **Synergistic Effect of FEFITC and IFN- $\alpha$ against Intraperitoneal M109 Tumor**




Fig. 16



**Folate-DNP Further Enhanced the Therapeutic Effect of  
a High Dose Combination of IL-2 and IFN- $\alpha$  in Mice  
with Pre-existing Anti-DNP Antibody**




Fig. 17